- Research works
- 24 ▲ 495% vs 2013–17
- Citations
- 331 13.6 per fractional work
- Top-10% rate
- 7.4% record average 16.5%
- Open access
- 57% world 28%
Not ranked overall: Xeris Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at Xeris Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Glycemic Control, Insulin Therapy, Diabetes, Type 1 Diabetes, Cardiovascular Disease, Continuous Glucose Monitoring, Hypoglycemia and Diabetes Mellitus.
- Immunotherapy
- Depression
- Pituitary Adenomas
- Cushing's Syndrome
- Oxidative Stress
- Fc Receptors
- Therapeutic Antibodies
- Critical Care
- Monoclonal Antibodies
- Cardiovascular Outcomes
- Diabetes Mellitus
- Continuous Glucose Monitoring
- Type 1 Diabetes
- Insulin Therapy
- Glycemic Control
- Diabetes
- Cardiovascular Disease
- Hypoglycemia
- Type 2 Diabetes
- Glucose Control
- Mortality
- Hyperglycemia
- Antibody Engineering
- Drug Discovery
- Growth Hormone
- Pancreatic Islets
- ß-Cell Dysfunction
- Epidemiology
- Immune Modulation
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 29 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 29 words, with their numbers
- Glycemic Control8▲ 235×4 topics
- Insulin Therapy7▲ 277×3 topics
- Diabetes4▲ 31×3 topics
- Type 1 Diabetes4▲ 168×2 topics
- Cardiovascular Disease4▲ 13×3 topics
- Continuous Glucose Monitoring3▲ 311×1 topic
- Hypoglycemia3▲ 311×1 topic
- Diabetes Mellitus3▲ 53×2 topics
- Type 2 Diabetes2▲ 52×2 topics
- Cardiovascular Outcomes2▲ 217×1 topic
- Glucose Control2▲ 217×1 topic
- Monoclonal Antibodies2▲ 62×3 topics
- Mortality2▲ 18×3 topics
- Critical Care2▲ 33×1 topic
- Hyperglycemia2▲ 73×1 topic
- Therapeutic Antibodies2▲ 59×2 topics
- Antibody Engineering2▲ 69×1 topic
- Fc Receptors2▲ 69×1 topic
- Drug Discovery2▲ 15×3 topics
- Oxidative Stress2▲ 3.3×3 topics
- Growth Hormone1▲ 64×2 topics
- Cushing's Syndrome1▲ 132×1 topic
- Pancreatic Islets1▲ 74×1 topic
- Pituitary Adenomas1▲ 132×1 topic
- ß-Cell Dysfunction1▲ 74×1 topic
- Depression1▲ 5.9×2 topics
- Epidemiology1◆ 1.14×4 topics
- Immunotherapy1▲ 7.0×3 topics
- Immune Modulation1▲ 29×2 topics
Which research topics does Xeris Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Pituitary Gland Disorders and Treatments, Diabetes Management and Research, Diabetes Treatment and Management and Myasthenia Gravis and Thymoma.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Pituitary Gland Disorders and Treatments Endocrinology, Diabetes and Metabolism 1 works
- 2 Diabetes Management and Research Endocrinology, Diabetes and Metabolism 1 works
- 3 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 1 works
- 4 Myasthenia Gravis and Thymoma Neurology 1 works
- 5 Adrenal Hormones and Disorders Endocrinology, Diabetes and Metabolism 0 works
- 6 Hyperglycemia and glycemic control in critically ill and hospitalized patients Endocrinology, Diabetes and Metabolism 0 works
- 7 Pancreatic function and diabetes Surgery 0 works
- 8 Chemokine receptors and signaling Oncology 0 works
- 9 Biosimilars and Bioanalytical Methods Immunology 0 works
- 10 Multiple Myeloma Research and Treatments Hematology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Xeris Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 495% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Austin
- The University of Texas at Austin
- Perfect Harmony Health
- Oracle (United States)
- Dynamic Systems (United States)
- The University of Texas System
- Office of the Attorney General
- Silicon Labs (United States)
- Texas Department of Transportation
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.